<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03171025</url>
  </required_header>
  <id_info>
    <org_study_id>HCI100769</org_study_id>
    <nct_id>NCT03171025</nct_id>
  </id_info>
  <brief_title>Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer</brief_title>
  <acronym>NEXT</acronym>
  <official_title>A Phase II Open Label Single Arm Study of Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, single arm, open label trial to evaluate the rate of failure free survival&#xD;
      at 2 years after start of chemoradiation with adjuvant nivolumab in adult subjects who&#xD;
      undergo chemoradiation for localized bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2017</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a phase 2, single arm, open label trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Two-year rate of failure-free survival (FFS)</measure>
    <time_frame>2 years</time_frame>
    <description>The definition of failure will include loco-regional recurrence, and distant recurrence. The primary endpoint of the FFS will be determined based on disease recurrence date defined as the time between the start date of chemoradiation and the date of first recurrence or non-cancer related death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of failure-free survival at two years in subjects with intact bladder (FFSIB).</measure>
    <time_frame>2 years</time_frame>
    <description>This will be measured only in subjects who do not have local recurrence requiring radical cystectomy. The endpoint of FFSIB will be determined based on disease recurrence date defined as the time between the start date of chemoradiation and the date of first recurrence or non-cancer related death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of acute and late grade 2 or higher treatment related Genitourinary, Gastrointestinal, hematologic and immune related adverse events.</measure>
    <time_frame>Patient safety will be evaluated throughout the treatment period and follow up (treatment with Nivolumab is expected to last 1 year for each patient and follow up for 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of treatment on Quality of Life</measure>
    <time_frame>Quality of life questionnaires done every 3 months while patients are on treatment for 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystoscopic Local Control</measure>
    <time_frame>Done at 6 months, 1 year and 2 years</time_frame>
    <description>Evaluate cystoscopic local control at 6 months, 1 year and 2 years post start of chemoradiation after censoring for distant recurrence. The endpoint will be measurement of local recurrence at 6 months, 1 year and 2 years as determined by cystoscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of salvage cystectomy</measure>
    <time_frame>During study treatment that is expected to last for 1 year</time_frame>
    <description>Evaluate the rate of salvage cystectomy. This will be measured by the endpoint of radical cystectomy for local recurrence during study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of distant failure free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate the rate of distant failure free survival at two years in subjects with intact bladder and those who discontinue study to undergo salvage cystectomy. This will be measured in subjects who do and do not have local recurrence requiring radical cystectomy during study treatment. The endpoint FFS will be determined based on disease recurrence date defined as the time between the start date of chemoradiation and the date of first distant recurrence or non-cancer related death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluate overall survival up to 5 years. This will be measured by the rate of death for up to 5 years from start of chemoradiation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Nivolumab, all patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab at a dose of 480 mg will be administered as an IV infusion over 60 minutes every 4 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 12 treatments over an expected duration of 1 year.</description>
    <arm_group_label>Nivolumab, all patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with muscularis propria invasion clinical stages 2 to 4 (T2-4b, N0 or N+, M0&#xD;
             or T1 with N+), who are not candidates for radical cystectomy.&#xD;
&#xD;
               -  Patients may have undergone partial cystectomy for removal of bladder tumor prior&#xD;
                  to chemoradiation. Patients who have M1 disease at any time prior to start of&#xD;
                  treatment are not eligible.&#xD;
&#xD;
               -  Staging is determined prior to chemoradiation&#xD;
&#xD;
          -  Patients have been evaluated by a urologic oncologist to determine eligibility for&#xD;
             radical cystectomy prior to chemoradiation. Patients may not be candidates for radical&#xD;
             cystectomy due to one or more reasons such as but not limited to comorbidities, age,&#xD;
             surgical risk or patient refusal to undergo radical cystectomy. Patients who refuse to&#xD;
             undergo radical cystectomy are not required to be evaluated by a urologic oncologist.&#xD;
&#xD;
          -  Patients must have histologically proven primary adenocarcinoma, transitional,&#xD;
             squamous-cell, or sarcomatoid carcinoma primary of the bladder, urethra, or lower&#xD;
             ureter.&#xD;
&#xD;
          -  Treating investigator has determined that the patients are not a candidate for radical&#xD;
             cystectomy. Patients have been evaluated by a urologic oncologist to determine&#xD;
             eligibility for radical cystectomy prior to chemoradiation. Patients may not be&#xD;
             candidates for radical cystectomy due to one or more reasons such as, but not limited&#xD;
             to, comorbidities, age, surgical risk, or patient refusal to undergo radical&#xD;
             cystectomy.&#xD;
&#xD;
          -  Tumor tissue from the most recently resected site of disease (preferable) or from the&#xD;
             transurethral resection that yielded the initial muscle invasive diagnosis must be&#xD;
             provided for biomarker correlative analyses. Enrollment is permitted if adequate&#xD;
             archived tissue is unavailable.&#xD;
&#xD;
          -  Patients must have received systemic radiosensitizing chemotherapy with definitive&#xD;
             pelvic radiation therapy. Patients may have received partial amount of chemotherapy&#xD;
             and radiation (both) to be eligible.&#xD;
&#xD;
          -  Platinum based chemotherapy prior to chemoradiation is permitted but not mandatory&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤2&#xD;
&#xD;
          -  Age ≥18.&#xD;
&#xD;
          -  Adequate bone marrow function White Blood Cell (WBC) &gt; 2000/µl, neutrophils &gt;1500/µl,&#xD;
             Hemoglobin &gt;9.0 g/dl.&#xD;
&#xD;
          -  Serum bilirubin and aminotransferase values less than 1.5 times the upper limit of the&#xD;
             normal range&#xD;
&#xD;
          -  Creatinine clearance of 20 ml/min or greater as measured by the Cockroft-Gault formula&#xD;
&#xD;
          -  Able to start study treatment within 90 days of completion of chemoradiation.&#xD;
&#xD;
          -  Female subject of childbearing potential should have a negative urine or serum&#xD;
             pregnancy within 72 hours prior to receiving the first dose of study medication. If&#xD;
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test&#xD;
             will be required.&#xD;
&#xD;
          -  Female subjects of childbearing potential should be willing to use 2 methods of birth&#xD;
             control or be surgically sterile, or abstain from heterosexual activity for the course&#xD;
             of the study through 5 months after the last dose of study medication. Subjects of&#xD;
             childbearing potential are those who have not been surgically sterilized or have not&#xD;
             been free from menses for &gt; 1 year.&#xD;
&#xD;
          -  Male subjects should agree to use an adequate method of contraception starting with&#xD;
             the first dose of study therapy through 7 months after the last dose of study therapy.&#xD;
&#xD;
          -  All toxicities attributed to prior anti-cancer therapy other than nephropathy,&#xD;
             neuropathy, hearing loss, alopecia and fatigue must have resolved to Grade 1 (NCI&#xD;
             CTCAE version 4.03) or baseline before administration of study drug. Subjects with&#xD;
             toxicities attributed to prior anti-cancer therapy which are not expected to resolve&#xD;
             and result in long lasting sequelae, such as neuropathy after platinum based therapy,&#xD;
             are permitted to enroll.&#xD;
&#xD;
          -  Able to provide informed consent and willing to sign an approved consent form that&#xD;
             conforms to federal and institutional guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of distant metastases or lymph node metastasis (es) that was not within the&#xD;
             radiation field.&#xD;
&#xD;
          -  Known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the&#xD;
             skin. A history of localized early stage malignancy that has undergone potentially&#xD;
             curative therapy or is low grade and does not require active treatment is allowed.&#xD;
&#xD;
          -  Diffuse bladder carcinoma in situ (CIS) that was not able to be encompassed in a boost&#xD;
             radiotherapy volume&#xD;
&#xD;
          -  Patients with inflammatory bowel disease&#xD;
&#xD;
          -  Patients with active, known or suspected autoimmune disease. Subjects with vitiligo,&#xD;
             type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only&#xD;
             requiring hormone replacement, psoriasis not requiring systemic treatment, or&#xD;
             conditions not expected to recur in the absence of an external trigger are permitted&#xD;
             to enroll.&#xD;
&#xD;
          -  Patients with a condition requiring systemic treatment with either corticosteroids&#xD;
             (&gt;10 mg daily prednisone equivalents) or other immunosuppressive medications within 14&#xD;
             day of study drug administration. Inhaled, ocular, intraarticular, intranasal and&#xD;
             topical steroids are permitted.&#xD;
&#xD;
          -  Patients with a known chronic immunocompromised state, HIV infection or active&#xD;
             Hepatitis B or Hepatitis C infection.&#xD;
&#xD;
          -  Pregnancy or women of childbearing potential not willing to use contraception and men&#xD;
             who are sexually active and not willing/able to use medically acceptable forms of&#xD;
             contraception and breast-feeding women not willing to stop breastfeeding during study.&#xD;
&#xD;
          -  Severe active co-morbidity as determined by the investigator or principal investigator&#xD;
&#xD;
          -  Life expectancy less than 2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hillary Finch</last_name>
    <phone>801-213-6126</phone>
    <email>hillary.finch@hci.utah.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hillary Finch</last_name>
      <phone>801-213-6126</phone>
      <email>hillary.finch@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Sumati Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 25, 2017</study_first_submitted>
  <study_first_submitted_qc>May 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2017</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Muscle Invasive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

